Literature DB >> 16395871

The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Maartje M L De Win1, Gerry Jager, Hylke K E Vervaeke, Thelma Schilt, Liesbeth Reneman, Jan Booij, Frank C Verhulst, Gerard J Den Heeten, Nick F Ramsey, Dirk J Korf, Wim Van den Brink.   

Abstract

This paper describes the objectives and methods of The Netherlands XTC Toxicity (NeXT) study focussing on the causality, course, and clinical relevance of ecstasy neurotoxicity. Previous studies suggest that ecstasy (3,4 methylene-dioxymethamphetamine, MDMA, XTC) is toxic toward brain serotonin axons, but most of these studies have serious methodological limitations. The current study is a combination of different approaches with three substudies: (1) a crosssectional substudy among heavy ecstasy users and controls with variation in drug use, which will provide information about potential neurotoxic consequences of ecstasy in relation to other drugs; (2) a prospective cohort substudy in ecstasy-naive subjects with high risk for future ecstasy use, which will provide information on the causality and short-term course of ecstasy use and potential neurotoxicity, and (3) a retrospective cohort substudy in lifetime ecstasy users and matched controls of an existing epidemiological sample that will provide information on long-term course and outcome of ecstasy use in the general population. Neurotoxicity is studied using (a) different imaging techniques (beta-CIT SPECT, 1H-MR spectroscopy, diffusion tensor imaging, perfusion weighted imaging and functional magnetic resonance imaging), and (b) neuropsychological and psychiatric assessments of memory, depression, and personality. The combined results will lead to conclusions that can be used in prevention messages, clinical decision making, and the development of an (inter)national ecstasy policy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16395871      PMCID: PMC6878462          DOI: 10.1002/mpr.6

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  91 in total

1.  Parkinsonism after taking ecstasy.

Authors:  S Mintzer; S Hickenbottom; S Gilman
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results.

Authors:  Liesbeth Reneman; Charles B L M Majoie; Herman Flick; Gerard J den Heeten
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

4.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users.

Authors:  D M Semple; K P Ebmeier; M F Glabus; R E O'Carroll; E C Johnstone
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

5.  Mental rotation of three-dimensional objects.

Authors:  R N Shepard; J Metzler
Journal:  Science       Date:  1971-02-19       Impact factor: 47.728

Review 6.  MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2004       Impact factor: 2.328

Review 7.  Serotonin in the regulation of brain microcirculation.

Authors:  Z Cohen; G Bonvento; P Lacombe; E Hamel
Journal:  Prog Neurobiol       Date:  1996-11       Impact factor: 11.685

8.  Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity.

Authors:  M J Morgan
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

9.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

10.  Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity.

Authors:  Liesbeth Reneman; Jan Booij; Jan B A Habraken; Kora De Bruin; George Hatzidimitriou; Gerard J Den Heeten; George A Ricaurte
Journal:  Synapse       Date:  2002-12-01       Impact factor: 2.562

View more
  10 in total

1.  Incidental head and neck findings on MRI in young healthy volunteers: prevalence and clinical implications.

Authors:  L Reneman; M M L de Win; J Booij; W van den Brink; G J den Heeten; N Freling; C B L M Majoie
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-21       Impact factor: 3.825

2.  Long-term effects of frequent cannabis use on working memory and attention: an fMRI study.

Authors:  Gerry Jager; Rene S Kahn; Wim Van Den Brink; Jan M Van Ree; Nick F Ramsey
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

3.  Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study.

Authors:  Gerry Jager; Maartje M de Win; Hylke K Vervaeke; Thelma Schilt; Rene S Kahn; Wim van den Brink; Jan M van Ree; Nick F Ramsey
Journal:  Psychopharmacology (Berl)       Date:  2007-05-03       Impact factor: 4.530

4.  Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users.

Authors:  Thelma Schilt; Maarten W J Koeter; Johan P Smal; Mathilde N Gouwetor; Wim van den Brink; Ben Schmand
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

5.  N-acetylaspartate (NAA) correlates inversely with cannabis use in a frontal language processing region of neocortex in MDMA (Ecstasy) polydrug users: a 3 T magnetic resonance spectroscopy study.

Authors:  Ronald L Cowan; James M Joers; Mary S Dietrich
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

6.  MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study.

Authors:  V Raj; H C Liang; N D Woodward; A L Bauernfeind; J Lee; M S Dietrich; S Park; R L Cowan
Journal:  J Psychopharmacol       Date:  2009-03-20       Impact factor: 4.153

7.  The Neurobiology of Cannabis Use Disorders: A Call for Evidence.

Authors:  Valentina Lorenzetti; Janna Cousijn; Nadia Solowij; Hugh Garavan; Chao Suo; Murat Yücel; Antonio Verdejo-García
Journal:  Front Behav Neurosci       Date:  2016-05-10       Impact factor: 3.558

8.  Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective.

Authors:  Kim P C Kuypers; Eef L Theunissen; Janelle H P van Wel; Elizabeth B de Sousa Fernandes Perna; Anke Linssen; Anke Sambeth; Benjamin G Schultz; Johannes G Ramaekers
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

9.  Decision making as a predictor of first ecstasy use: a prospective study.

Authors:  Thelma Schilt; Anneke E Goudriaan; Maarten W Koeter; Wim van den Brink; Ben Schmand
Journal:  Psychopharmacology (Berl)       Date:  2008-11-20       Impact factor: 4.530

10.  Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.

Authors:  Sascha B Thal; Miriam J J Lommen
Journal:  J Contemp Psychother       Date:  2018-01-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.